Osaka, Japan and Bridgewater, New Jersey, August 4, 2026
NIPRO CORPORATION, through its U.S.-based subsidiary NIPRO Medical Corporation, has announced the U.S. commercial launch of ELISIO™-HX, a medium cut-off dialyzer incorporating super high-flux membrane technology for expanded hemodialysis. The commercial introduction follows recent U.S. FDA 510(k) clearance for ELISIO-HX and enables dialysis providers nationwide to access NIPRO’s expanded hemodialysis approach using existing dialysis infrastructure. The technology is designed to enhance the removal of larger middle molecules, substances that conventional high-flux dialysis may not clear as effectively and that have been associated with inflammation and other complications in patients receiving dialysis. By combining enhanced filtration capabilities with compatibility with established hemodialysis equipment, NIPRO aims to provide a practical pathway for incorporating advanced dialysis technology into routine kidney care without requiring significant changes to existing treatment environments.
ELISIO-HX Targets Enhanced Middle Molecule Removal
A central feature of ELISIO-HX is its precisely engineered membrane pore structure, designed to extend the removal profile for larger middle molecules while maintaining albumin retention. Preserving albumin is an important consideration because excessive albumin loss may affect patients’ nutritional status. Dialysis providers have long explored approaches capable of removing a broader range of uremic toxins, but adoption of some advanced therapies can be affected by factors including cost, supply availability, operational complexity and infrastructure requirements. NIPRO developed ELISIO-HX to provide enhanced middle molecule clearance through a dialyzer that can be incorporated into established treatment models. The company describes its approach as expanded hemodialysis using a super high-flux membrane, or HDs. The U.S. launch builds on experience with ELISIO-HX across Asia, Europe and Latin America, where the technology has already been used in multiple healthcare environments.
Existing Dialysis Infrastructure Supports Clinical Adoption
One of the key potential advantages of ELISIO-HX is its compatibility with existing hemodialysis infrastructure. According to NIPRO, providers can introduce the technology without purchasing new dialysis machines, fundamentally redesigning treatment workflows or extensively retraining clinical staff. This implementation profile could make expanded hemodialysis more accessible across a range of dialysis centers. The company also notes that ELISIO-HX does not depend on some of the higher blood-flow requirements or more complex treatment conditions associated with certain alternative approaches, potentially supporting use across a broader dialysis population, including patients with vascular access limitations. For healthcare providers balancing clinical innovation with operational efficiency, the ability to integrate an advanced dialyzer into existing treatment schedules, staffing models and equipment environments could facilitate adoption while maintaining familiar care pathways.
Advertisement
FDA Clearance Drives U.S. Commercial Expansion
The FDA-cleared commercial launch marks a significant expansion of NIPRO’s kidney care portfolio in the United States and brings its global experience with ELISIO-HX into the U.S. dialysis market. NIPRO is positioning the technology as a scalable approach to expanded hemodialysis that can increase access to enhanced middle molecule removal while minimizing additional infrastructure requirements. The company’s global manufacturing and supply capabilities are also expected to support broader availability as dialysis providers evaluate the technology for routine practice. The introduction comes as nephrologists and dialysis organizations continue to seek technologies capable of improving treatment options while maintaining efficient clinical operations. With ELISIO-HX now commercially available following FDA 510(k) clearance, NIPRO is expanding the range of dialyzer technologies available to U.S. providers and reinforcing its presence in advanced renal care. The launch represents an important MedTech commercialization milestone, combining regulatory clearance, membrane engineering and practical implementation within established dialysis systems to support the evolving needs of patients requiring long-term hemodialysis.
Source: NIPRO press release
